TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JULY 12, 2021

July 5, 2021 – July 9, 2021. CSE: MSET) revealed additional preclinical data showing strong efficacy and improved safety in a head-to-head comparison with psilocybin. PsyIndex Weekly Update. The PsyIndex moved marginally lower last week, giving up some gains from the prior week. Market Performance. Powered by.

Treatment 66

Treatment Decriminalization Pharmaceutical Data 66

TheAnswerPage

NOVEMBER 19, 2021

According to a study published in the October 2021 edition of Cancer, what is the most common time for breast cancer patients to use cannabinoid-based products: pre-treatment, during treatment or after treatment? 24% used the cannabinoids pre-treatment, 79% during treatment and 54% after treatment.

Treatment 52

Treatment Cannabinoids Data Patients 52

Cannabis Law Report

DECEMBER 11, 2021

The UK’s first and highest-rated medical cannabis clinic, Sapphire Medical Clinics , has today announced that it is reducing the cost of its consultations and appointments for patients enrolled through the Sapphire Access Scheme. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52

Access Patients Chronic Pain Treatment 52

Cannabis Law Report

AUGUST 12, 2021

Net loss for the six months ended 30 June 2021 was $30.2 Net loss for the six months ended 30 June 2021 was $30.2 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. The analogy would be this. million, or $0.79

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

SpeedWeed

FEBRUARY 21, 2021

February 18, 2021. | If successful, data from (Kaminski’s) pre-clinical study would be used as part of the support for an Independent New Drug filing with the FDA,” said Small-Howard. The post Cannabis mixtures studied as treatment for COVID inflammation appeared first on SpeedWeed. Published.

Treatment 52

Treatment Research and Development Cannabinoids Data 52

Cannabis Law Report

OCTOBER 15, 2021

The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., DNA variations or polymorphisms) in patients with African ancestry. Both meetings are being held virtually.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

Cannabis Law Report

JANUARY 6, 2022

This blog post will explain how psilocybin patenting and other factors could make Oregon’s psilocybin program prohibitively expensive for low-income patients, and how big pharma is maneuvering to monopolize psychedelic therapy. patent awarded to COMPASS back in March 2021. Threat to Patient Access in Oregon.

Access 52

Access Patients Research and Development Treatment 52

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

JUNE 1, 2021

TORONTO, June 01, 2021 (GLOBE NEWSWIRE) — via InvestorWire – RYAH Group, Inc. The 5-year study is expected to cover tens of thousands of patients suffering from chronic pain, which makes it one of the largest and most ambitious research projects to be conducted in the plant-based treatment arena. About RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

AUGUST 3, 2021

Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. Data Bridge sees strong psychedelics growth.

Research and Development 105

Research and Development Data Conditions Therapy 105

Cannabis Law Report

JUNE 23, 2021

TORONTO, June 23, 2021 (GLOBE NEWSWIRE) — RYAH Group, Inc. Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. billion, servicing nearly 340,000 active patients. in real terms to £4.97

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

SEPTEMBER 23, 2021

This Was the World’s First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction. Toronto, Ontario, Sep 23, 2021 (Newsfile Corp via COMTEX) — Toronto, Ontario–(Newsfile Corp. – September 23, 2021) – Awakn Life Sciences Corp., (NEO: Treatment of AUD rates are low at 16%.

Research and Development 52

Research and Development Therapy Treatment Data 52

Cannabis Law Report

OCTOBER 29, 2021

NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. We expect to report this data as it becomes available and after submission to the FDA. During the six months ended September 30, 2021, the Company raised approximately $4.1

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Veriheal

MAY 31, 2022

According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. 1, 2020, and July 31, 2021—a 43% increase from the same period a year before. A 2019 study found that 76% of patients in the U.S. This trend dates back to the 1990s when U.S.

Programs 52

Programs Chronic Pain Treatment Conditions 52

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

SEPTEMBER 15, 2021

More than 100 people in the US have been hospitalized in 2021 after using Delta-8 THC products, federal health regulators warned Tuesday. Of the 22 patients, 19 experienced adverse events after ingesting delta-8 THC-containing food products (e.g., 39% involved pediatric patients less than 18 years of age. brownies, gummies).

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

DECEMBER 26, 2021

December 17, 2021 ·. – December 16, 2021) – Entheon Biomedical Corp. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. US Provisional Patent Filed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

AUGUST 4, 2021

The Core Business delivered strong organic growth 13 in H1 2021 (17% year-on-year) despite some of Eurofins’ businesses remaining affected by lockdowns during H1 2021. The Core Business delivered strong organic growth 13 in H1 2021 (17% year-on-year) despite some of Eurofins’ businesses remaining affected by lockdowns during H1 2021.

Business 105

Business Research and Development Environment Food 105

The Cannigma

MARCH 2, 2021

They argued that their findings suggest that doctors “outside of the VHA system who treat veteran patients may need to take the lead in conversations surrounding medical marijuana as a treatment option.”. While medical marijuana is a legal treatment option in 33 states and Washington D.C., Pain management was mentioned by 7.8%

Research and Development 143

Research and Development Treatment Chronic Pain Sleep 143

Cannabis Law Report

AUGUST 17, 2021

Improving Patient Outcomes with Real-time Feedback via Smart Inhalers and Portable and Lightweight Oxygen Concentrators for Increasing Home-Based Therapy is a Key Growth Opportunity. Therapeutic Medical Devices are Preferred by Physicians and Patients for Acute and Chronic Respiratory Conditions. The Strategic Imperative. Cognita Labs.

Research and Development 98

Research and Development Clinical Trials Concentrates Patients 98

Cannabis Law Report

JULY 19, 2021

July 19, 2021 07:58 ET | Source: Potbotics, Inc. Toronto, July 19, 2021 (GLOBE NEWSWIRE) — via InvestorWire — RYAH Group, Inc. The RYAH MD platform is designed for use by healthcare professionals to remotely monitor and control their patients’ dosing regimens with RYAH’s suite of dose-measuring products.

Therapy 76

Therapy Data Research and Development Events 76

Healer

MARCH 26, 2021

Sulak in 2016 that showed 85% of 525 of his practice’s patients reported a decrease in or cessation of opioid use when using medical cannabis. This article by Hannah Laclaire was originally published by the Portland Press Herald on March 19, 2021. Dr. Sulak’s Cannabis and Opioid Guide. Play video.

Chronic Pain 52

Chronic Pain Therapy Data Patients 52

Healer

MARCH 26, 2021

Sulak in 2016 that showed 85% of 525 of his practice’s patients reported a decrease in or cessation of opioid use when using medical cannabis. This article by Hannah Laclaire was originally published by the Portland Press Herald on March 19, 2021. Dr. Sulak’s Cannabis and Opioid Guide. Play video.

Chronic Pain 52

Chronic Pain Therapy Data Patients 52

Healer

MARCH 26, 2021

Sulak in 2016 that showed 85% of 525 of his practice’s patients reported a decrease in or cessation of opioid use when using medical cannabis. This article by Hannah Laclaire was originally published by the Portland Press Herald on March 19, 2021. Dr. Sulak’s Cannabis and Opioid Guide. Play video.

Chronic Pain 52

Chronic Pain Therapy Data Patients 52

Cannabis Law Report

AUGUST 24, 2022

The third Cannabis as Medicine Survey (CAMS20) follows on from CAMS16 and CAMS18, and includes 1,600 people using medical cannabis between September 2020 and January 2021. These include safer routes of administration, greater certainty of access, and better communication between patients and doctors.

Medicine 52

Medicine Legalization Chronic Pain Access 52

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. PRESS RELEASE. ” About COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

NOVEMBER 3, 2021

Khiron in the United Kingdom The company is pursuing a consistent approach to improve patient access to medical cannabis and to develop the market for medical cannabis treatments in the UK. This is a great milestone for Khiron and will contribute significantly to the dynamics of developing a market for medical cannabis in the UK.

Therapy 52

Therapy Access Patients Treatment 52

Cannabis Law Report

SEPTEMBER 1, 2021

As of start of business Wednesday, September 1, the Commission reported licensees have generated $844 million since January 1, already making 2021 a record sales year thus far. The Commission’s overall staff has increased to 84 employees, with 17 new employees joining the agency in 2021 and spanning nearly every department.

Marijuana 100

Marijuana Seed-To-Sale Safety Data 100

SpeedWeed

AUGUST 22, 2021

A report released by the MS Society states that not nearly enough medical cannabis patients have been able to obtain medical cannabis through the National Health Service (NHS), despite research and firsthand accounts of its effectiveness as a medicine for MS patients. treatments.” . deserves access to effective?treatments.”

Sleep 52

Sleep Access Patients Treatment 52

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 105

CBD Data Sleep Clinical Trials 105

Healer

MARCH 26, 2021

March 19, 2021. Gresh has joined a growing number of patients who swear by medical cannabis not only as a treatment option for chronic pain, but also as a substitute for prescription opioids used in pain management. Others aren’t so sure. This article was originally published in the Portland Press Herald.

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

Cannabis Law Report

JULY 6, 2021

July 06, 2021 08:30 ET | Source: Ehave. MIAMI, July 06, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Bankole Johnson was featured in a March 5 th 2021 Forbes article, “Dr. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. ” About Ehave, Inc. Ehave, Inc.

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

SpeedWeed

MARCH 6, 2021

Cannabis Voter Project (@Cannabis_Voter) March 3, 2021. Forcing patients to purchase more. Doing so, Pollara wrote, would effectively force a 50% to 150% tax on patients. It is also the one which produces the most and strongest medicinal effects for patients. NORML (@NORML) March 4, 2021. Feinstein nor Sen.

THC 52

THC Patients Law Chronic Pain 52

Cannabis Law Report

NOVEMBER 9, 2021

(“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced the official, completed acquisition of Ketamine Wellness Centers Arizona LLC (“KWC”), becoming the largest chain of wellness centers providing ketamine treatments in the U.S.

Treatment 52

Treatment Therapy Media Access 52

Canna Law Blog

DECEMBER 16, 2021

On Monday, November 13, 2021, New York Assemblyman Pat Burke introduced medical psilocybin legislation. Qualifying medical practitioners would need to take a two-hour training course provided by the Department of Health in order to certify patients for psilocybin treatment. Rules and Restrictions.

Legislation 97

Legislation Treatment Therapy Conditions 97